CG
CLDX icon

Cutler Group’s Celldex Therapeutics CLDX Stock Holding History

Cutler Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,600
Closed -$4K – 2439
2023
Q4 		$4K Buy
19,600
+16,900
+626% +$497K ﹤0.01% 2805
2023
Q3 		$16K Sell
2,700
-400
-13% -$12.5K ﹤0.01% 2182
2023
Q2 		$22K Buy
3,100
+1,000
+48% +$33.7K ﹤0.01% 1794
2023
Q1 		$16K Sell
2,100
-5,100
-71% -$220K ﹤0.01% 2029
2022
Q4 		$3K Sell
7,200
-100
-1% -$3.57K ﹤0.01% 3442
2022
Q3 		$22K Buy
7,300
+3,400
+87% +$104K ﹤0.01% 2535
2022
Q2 		$66K Buy
3,900
+500
+15% +$14.5K ﹤0.01% 1733
2022
Q1 		$59K Sell
3,400
-3,700
-52% -$118K ﹤0.01% 2113
2021
Q4 		$12K Buy
+7,100
New +$309K ﹤0.01% 3525
2017
Q3 		– Sell
-20
Closed -$2K – 5937
2017
Q2 		$2K Hold
20
– – ﹤0.01% 5451
2017
Q1 		$1K Hold
20
– – ﹤0.01% 5764
2016
Q4 		$1K Hold
20
– – ﹤0.01% 5914
2016
Q3 		$1K Sell
20
-67
-77% -$4.17K ﹤0.01% 6046
2016
Q2 		$12K Sell
87
-1,506
-95% -$95.6K ﹤0.01% 3915
2016
Q1 		$381K Sell
1,593
-1,194
-43% -$134K 0.03% 643
2015
Q4 		$211K Buy
+2,787
New +$608K 0.01% 1149

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Cutler Group's CLDX Position: Q1 2024 in Review

Cutler Group sold out of Celldex Therapeutics (CLDX) in Q1 2024, closing a stake of 1,460 shares — an estimated $57K sold.

Cutler Group first reported a position in CLDX in Q4 2015 and held it in 19 quarters. The position peaked at $746K in Q4 2015. 197 funds tracked by Wall St. Rank hold CLDX as of Q1 2024.

  • Cutler Group reported no remaining Celldex Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 1,460 Celldex Therapeutics shares in Q1 2024, an estimated $57K.
  • Cutler Group first reported a position in Celldex Therapeutics in Q4 2015 and held it in 19 quarters.
  • Cutler Group's Celldex Therapeutics position peaked at $746K in Q4 2015.
  • 197 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.